NEW HAVEN, Conn., Dec. 3, 2015 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has three presentations, two oral and one poster, at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015.
All presentations focus on furthering Arvinas' understanding of BRD4 degraders in models of hematological cancers; specifically, in preclinical models of acute leukemias, multiple myeloma and lymphoma, treatment with BRD4 degraders demonstrated substantial anti-cancer activity. Arvinas has created potent and selective BRD4 degraders using its PROTAC technology, and the presentations derive from work performed both at Arvinas and in collaboration with researchers at The University of Texas MD Anderson Cancer Center.
Oral presentation details
BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity against Acute Leukemias and Overcomes Stroma Mediated Resistance by Modulating Surface Expression of CXCR4 (Abstract #675)
Speaker: Dr. Sujan Piya, The University of Texas MD Anderson Cancer Center
Session Title: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Acute Myeloid Leukemia: An Understanding of Molecular Mechanisms Guides Rational Drug Combinations
Session Date and Time: Monday, December 7, 2015; 2:45 PM – 4:15 PM; Presentation at 3:15 PM
Session Location: Orange County Convention Center, W307
Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma (Abstract #917)
Speaker: Dr, Xiaohui Zhang, The University of Texas MD Anderson Cancer Center
Session Title: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Targets and Therapeutic Approaches
Session Date and Time: Monday, December 7, 2015; 6:15 PM – 7:45 PM; Presentation at 7:15 PM
Session Location: Orange County Convention Center, W304ABCD
Poster presentation details
BRD4 Degradation by Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL (Abstract #2050)
Speaker: Dr. Jim Winkler, Chief Scientific Officer Arvinas
Session Title: 802. Chemical Biology and Experimental Therapeutics: Poster I
Session Date and Time: Saturday, December 5, 2015; 5:30 PM – 7:30 PM
Session Location: Orange County Convention Center, Hall A
About Arvinas
Arvinas is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients. To address these pathological intracellular proteins, Arvinas is developing a new drug paradigm based on the elimination of these proteins. Our innovative protein degradation technology uses small molecule drugs to "tag" specific proteins to be degraded by the ubiquitin/proteasome system (UPS), which is responsible for the normal turnover of most proteins within the cell.
Based on groundbreaking research conducted at Yale University by our Founder and Chief Scientific Advisor, Craig Crews, PhD, Arvinas has developed a platform technology to induce the loss of intracellular proteins: Proteolysis-Targeting Chimera (PROTAC). The ability of PROTAC-based drugs to induce protein degradation (instead of protein inhibition) offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands our ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.
SOURCE Arvinas